Pilat M J, Lehr J E, Quigley M M, Pienta K J
Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109-0946, USA.
Oncol Rep. 1998 Jul-Aug;5(4):889-92. doi: 10.3892/or.5.4.889.
Most deaths from cancer result from the metastatic spread of the disease. The antidiuretic amiloride has been shown to inhibit tumor growth and metastasis in several tumor systems. The object of these studies was to examine the effect on the in vitro and in vivo tumor growth and metastasis in the MatLyLu subline of the Dunning model of rat prostate cancer. In vitro, amiloride was found to have cytotoxic effects only at high concentrations, with an IC50 of 100 microg/ml. In vitro analysis of the ability of amiloride to inhibit invasion of MLL cells demonstrated that this drug was ineffective at all concentrations examined. In vivo, amiloride did not inhibit tumor growth or metastases development. Our studies demonstrate that amiloride does not have activity in this model of prostate cancer and suggest it may not be an appropriate therapy for the treatment of prostate cancer.
大多数癌症死亡是由疾病的转移扩散导致的。抗利尿药阿米洛利已被证明在多种肿瘤系统中可抑制肿瘤生长和转移。这些研究的目的是检验其对大鼠前列腺癌邓宁模型的MatLyLu亚系体外和体内肿瘤生长及转移的影响。在体外，仅在高浓度时阿米洛利才具有细胞毒性作用，半数抑制浓度为100微克/毫升。对阿米洛利抑制MLL细胞侵袭能力的体外分析表明，在所检测的所有浓度下该药物均无效。在体内，阿米洛利不抑制肿瘤生长或转移的发展。我们的研究表明，阿米洛利在该前列腺癌模型中无活性，并提示它可能不是治疗前列腺癌的合适疗法。
